SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
DermTech, Inc. (DMTK) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+7878.7%).
- Analyst consensus target $7.50 (+7878.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 44/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DMTK
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.20
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.09
Book Value / Share$0.00
Revenue / Share$0.47
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$7.50 (+7878.7%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$-0.65 |
$0.00 |
$-2.23M |
- |
| 2013 |
$-1.10 |
$0.00 |
$-5.18M |
- |
| 2017 |
$0.00 |
$0.00 |
$-60.00 |
- |
| 2018 |
$0.36 |
$0.00 |
$856.41K |
- |
| 2019 |
$-3.13 |
$3.36M |
$-21.9M |
-651.1% |
| 2020 |
$-2.05 |
$5.89M |
$-36.48M |
-619.8% |
| 2021 |
$-2.71 |
$11.84M |
$-78.34M |
-661.7% |
| 2022 |
$-3.88 |
$14.52M |
$-116.68M |
-803.7% |
| 2023 |
$-3.09 |
$15.3M |
$-100.89M |
-659.6% |
